The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Gastrointestinal Oncology

• Publication date

  2014-04-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.3978/j.issn.2078-6891.2014.001PMID 24772334PMCID PMC3999628
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base

  2014cited by this paper
• A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

  2012influential reference
• Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations.

  2012cited by this paper
• Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning.

  2012cited by this paper
• Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.

  2011influential reference
• Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning.

  2011cited by this paper
• Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.

  2011influential reference
• Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas

  2009cited by this paper
• DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

  2009influential reference
• Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

  2008cited by this paper
• Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

  2007cited by this paper
• Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

  2007cited by this paper
• A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.

  2007cited by this paper
• Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

  2005influential reference
• The National Cancer Data Base: A clinical surveillance and quality improvement tool

  2004influential reference
• Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.

  2004cited by this paper
• The National Cancer Data Base: a clinical surveillance and quality improvement tool.

  2004cited by this paper
• Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer.

  2004cited by this paper
• Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

  2001influential reference
• Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma

  2000influential reference
• Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

  1993cited by this paper
• Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group

  1981influential reference

• Escalated‐dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States

  2024cites this paper
• Discovery of the inhibitor of DNA binding 1 as a novel marker for radioresistance in pancreatic cancer using genome-wide RNA-seq

  2022cites this paper
• Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer.

  2021cites this paper
• Association of survival with stereotactic body radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer

  2021cites this paper
• TSPAN1 upregulates MMP2 to promote pancreatic cancer cell migration and invasion via PLCγ

  2019cites this paper
• A preferred patient decubitus positioning for magnetic resonance image guided online adaptive radiation therapy of pancreatic cancer

  2019cites this paper
• Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence.

  2018cites this paper
• Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma

  2018cites this paper
• Silencing Tspan1 inhibits migration and invasion, and induces the apoptosis of human pancreatic cancer cells

  2018cites this paper
• Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer

  2018influential citation
• EGLN Inhibition Reduces Gastrointestinal Radiation Toxicity and Improves Survival in a Murine Model of Locally Advanced Pancreatic Cancer

  2017cites this paper
• Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy.

  2016cites this paper
• Brachytherapy improves survival in primary vaginal cancer.

  2016cites this paper
• Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.

  2015cites this paper
• The Clinical Management of Pancreatic Cancer

  2014cites this paper